The clinical course of autoimmune and infectious disease varies greatly, even between individuals with the same condition. An understanding of the molecular basis for this heterogeneity could lead to significant improvements in both monitoring and treatment. During chronic infection the process of T-cell exhaustion inhibits the immune response, facilitating viral persistence 1 . Here we show that a transcriptional signature reflecting CD8 T-cell exhaustion is associated with poor clearance of chronic viral infection, but conversely predicts better prognosis in multiple autoimmune diseases. The development of CD8 T-cell exhaustion during chronic infection is driven both by persistence of antigen and by a lack of accessory 'help' signals. In autoimmunity, we find that where evidence of CD4 T-cell co-stimulation is pronounced, that of CD8 T-cell exhaustion is reduced. We can reproduce the exhaustion signature by modifying the balance of persistent stimulation of T-cell antigen receptors and specific CD2-induced costimulation provided to human CD8 T cells in vitro, suggesting that each process plays a role in dictating outcome in autoimmune disease. The 'non-exhausted' T-cell state driven by CD2-induced co-stimulation is reduced by signals through the exhaustion-associated inhibitory receptor PD-1, suggesting that induction of exhaustion may be a therapeutic strategy in autoimmune and inflammatory disease. Using expression of optimal surrogate markers of co-stimulation/exhaustion signatures in independent data sets, we confirm an association with good clinical outcome or response to therapy in infection (hepatitis C virus) and vaccination (yellow fever, malaria, influenza), but poor outcome in autoimmune and inflammatory disease (type 1 diabetes, anti-neutrophil cytoplasmic antibody-associated vasculitis, systemic lupus erythematosus, idiopathic pulmonary fibrosis and dengue haemorrhagic fever). Thus, T-cell exhaustion plays a central role in determining outcome in autoimmune disease and targeted manipulation of this process could lead to new therapeutic opportunities.
In a complex set of data such as the transcriptome, similar measurements may be grouped together by network analysis to form discrete modules that can highlight novel pathways contributing to the pathogenesis of complex diseases. We have previously shown that a CD8 T-cell transcriptional signature in patients with multiple immunemediated diseases can predict a subsequent relapsing disease 2, 3 . However, the biology underlying this observation was not clear. We therefore applied weighted gene co-expression network analysis (Extended Data Fig. 1 ) to the transcriptomes of purified CD4 and CD8 T cells isolated from a prospective cohort of 44 patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) having active, untreated disease 2 ( Supplementary Table 1 ) to further explore the mechanisms driving relapsing autoimmunity. Modules of genes ( Fig. 1a , rows) were summarized as 'eigengene' profiles ( Fig. 1b , f) that were correlated with clinical variables (Fig. 1a , i, columns) and visualized in the form of a heat map (Fig. 1a, i) . Modules derived both from CD8 ( Fig. 1a-d ) and from CD4 ( Fig. 1f-i ) T-cell transcriptomes showed strong correlation with disease outcome but not activity, and were co-correlated ( Fig. 1e ) despite being mutually exclusive (Supplementary Table 2 ). A similar analysis using a cohort of 23 patients with systemic lupus erythematosus (SLE) also presenting with active, untreated disease (Supplementary Table 3 ) 2 identified analogous CD8 and CD4 T-cell expression modules (Extended Data Fig. 2 ) that again correlated with clinical outcome but not disease activity. By contrast a type 1 interferon (IFN) response signature was associated with disease activity but not with long-term outcome (Extended Data Fig. 2f ), consistent with previous reports 4 .
Next, we reasoned that genes within co-correlated modules in related cell types might inform the biology of relapsing disease. By selecting CD4 T-cell modules showing significant, strong correlation with relapse rate and performing network enrichment analysis, we identified a module corresponding to CD4 T-cell co-stimulation (Extended Data Figs 1f, g and 3a and Supplementary Tables 2 and  3 ). By way of validation, we repeated this analysis using an independent co-expression network algorithm that similarly demonstrated association between a CD4 co-stimulation module and clinical outcome (Supplementary Table 5 ). The independent association of modular signatures with clinical outcome (Fig. 1a , i) was confirmed using multiple linear regression modelling (Extended Data Fig. 3b-e ) and was only apparent during active disease (Extended Data Fig. 3f and Supplementary Discussion).
During chronic viral infection, CD8 T-cell memory responses are exquisitely dependent on CD4 T-cell co-stimulation 5, 6 , which can lead to the resolution of chronic infection both in mice 1 and in humans 7 . When antigen persists in the absence of co-stimulation, CD8 T cells become 'exhausted' 1 , a phenotype characterized by progressive loss of effector function, persistent high expression of inhibitory receptors and profound changes in gene expression, distinct from those seen in effector, memory or anergic T cells 8 . Although mice lacking inhibitory receptors have an increased incidence and severity of autoimmunity 9,10 , a specific role for exhaustion in dictating the outcome of autoimmune responses has not been demonstrated.
We hypothesized that CD4 T-cell signals may be important in limiting exhaustion towards persistent self-antigen during autoreactive immunity, analogous to responses during persistent infection. We therefore used gene set enrichment analysis (GSEA 11 ) to test for altered expression of transcriptional signatures reflecting T-cell exhaustion (and other T cell-related phenotypes) between subgroups of patients defined by the CD8 modular analysis, who go on to develop relapsing or quiescent autoimmunity ( Fig. 2a ). Using this approach, we observed that genes specifically downregulated in exhausted CD8 T cells during chronic murine lymphocytic choriomeningitis virus (LCMV) infection (but not altered in memory, naive or effector cells; Supplementary Table 6 (ref. 8)) were similarly downregulated in CD8 T cells from patients at low risk of subsequent relapse ( Fig. 2b and Extended Data Figs 3g-i and 4).
During chronic murine LCMV infection, T-cell exhaustion is driven by coordinate upregulation of multiple co-inhibitory receptors 12 that signal synergistically to produce a state of generalized immunosuppression 13 . In autoimmunity, these receptors were not coordinately upregulated as a group. Instead, patients with good prognosis from each disease were characterized by upregulation of a distinct subset of exhaustion-associated co-inhibitory receptors (Fig. 2c) . Although a divergence from the murine LCMV model, T-cell exhaustion accompanied by expression of a limited subset of co-inhibitory receptors is similar to that described in intratumoural CD8 T cells 14 , which are a target for checkpoint therapy (Extended Data Fig. 4i) 15, 16 .
To confirm whether exhaustion was associated with clinical outcome, we used the murine CD8 T-cell exhaustion signature (Supplementary Table 6 Fig. 2j -l). In each case this identified a subgroup of patients with both early ( Fig. 2e , h, k) and recurrent ( Fig. 2f , i, l) relapses. Whereas CD8 exhaustion was associated with poor outcome in viral infection, in every case it predicted favourable prognosis in autoimmune and inflammatory disease ( Fig. 2d-l) . Again, independent association with outcome was confirmed using multiple linear regression models (Extended Data Fig. 3d, e ). Together, these data demonstrate that a transcriptional signature of relative CD8 T-cell exhaustion, similar to that determining outcome in chronic viral infection and cancer, is apparent during active, untreated disease in patients with favourable long-term outcome in multiple autoimmune and inflammatory diagnoses.
CD8 T-cell exhaustion is characterized by high expression of coinhibitory receptors (such as PD-1 (ref. 12)) and low expression of nascent memory markers (such as interleukin (IL)-7R 17 ) and is promoted both by the persistence of antigen 18 and by a lack of accessory co-stimulation 6 . To understand signals driving exhaustion and outcome in autoimmunity, we attempted to recreate the outcomeassociated transcriptional signatures using variable T-cell antigen 
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receptor (TCR) signal duration and co-stimulation of primary human cells in vitro. We stimulated purified human CD8 T cells using a magnetic bead conjugated with antibodies targeting co-stimulatory molecules ( Fig. 3a ) and measured expression of IL-7R and PD-1 expression ( Fig. 3b -i and Extended Data Fig. 5a -g) as markers indicating an exhausted phenotype. Comparison between persistent (6 days) and transient (36 h) TCR stimulation showed that IL-7R expression returned on a proportion of cells after several divisions when the TCR stimulus was removed ( Fig. 3c ) but failed to do so if it persisted ( Fig. 3d, g ). We then systematically tested whether costimulatory molecules, identified from the CD4 T-cell network analysis described above ( Fig. 1i and Extended Data Figs 3a and 5h-k), could overcome the effect of persistent TCR stimulation during in vitro differentiation. We found that specific co-stimulation with anti-CD2 ( Fig. 3e, h ), but not with other stimuli such as IFN-a or anti-CD40, expression in healthy age-, sex-and HLA-matched controls (i, blue) and in pre-T1D cases (n 5 5, red), two of which seroconvert to islet-cell antibodies (j, black line) and three of which develop T1D (k, black line).
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resulted in maintained IL-7R expression, limited upregulation of PD-1 and enhanced cell survival ( Fig. 3e and Extended Data Fig. 5 ). While CD8 exhaustion is known to limit viral control during chronic infection, exhausted cells may be restored to useful function by blocking inhibitory signalling through PD-1 (ref. 19) . Enhancing co-inhibitory signals is therefore a logical therapeutic strategy in autoimmune disease, aiming to facilitate exhaustion despite high levels of co-stimulation that would otherwise be predicted to result in an aggressive relapsing disease course. To test this concept, primary human CD8 T cells were co-stimulated during persistent TCR signalling as above ( Fig. 3e) in the presence or absence of a bead-bound Fc-chimaeric version of the principal PD-1 ligand, PDL-1 (Fig. 3a, f) . When added to CD2-co-stimulated CD8 T-cell cultures, increased PD-1/PDL-1 signalling suppressed differentiation of a non-exhausted IL-7R hi subpopulation ( Fig. 3f , i).
To define the phenotype of T-cell exhaustion more robustly, as small numbers of surface markers are insufficient, we analysed the transcriptome of CD8 T cells exposed to persistent stimulation with and without CD2 signalling (Supplementary Table 7 ). This CD2 response signature characterized exhausted cells but not effector or memory subsets (by GSEA; Fig. 3j -l). Consistent with this, patient clusters generated using the CD2 response signature recreated subgroups similar to those generated using the murine LCMV CD8 exhaustion signature (Figs 2d, g, j and 3m-o). Thus, CD2 signalling during persistent TCR stimulation of primary human CD8 T cells prevents the development of transcriptional changes characteristic of exhaustion, recreating transcriptional signatures associated with opposing outcomes in viral infection and autoimmunity.
To confirm that the transcriptional signatures reflected the development of functional exhaustion in vitro, we showed that cells appearing exhausted (IL-7R lo PD-1 hi ) also expressed markers of apoptotic resistance (BCL2 lo ), characteristic cytokine patterns (IFN-c lo IL-10 hi ) and showed diminished survival on re-stimulation (Extended Data Fig. 6a-e ). There was no evidence of preferential accumulation of CD8 T-cell subsets after CD2-induced co-stimulation (Extended Data Fig. 6f -h). These data highlight the importance of CD2 signalling in limiting the development of CD8 T-cell exhaustion in the face of persistent TCR simulation, and provide a starting point for more sophisticated attempts to therapeutically exhaust an autoimmune response in a targeted fashion.
We next aimed to independently validate the association between the balance of CD4 co-stimulation and CD8 exhaustion with clinical outcome using published data sets. Most of these profile unseparated peripheral blood mononuclear cells (PBMCs), in which T-cellintrinsic signatures are not readily apparent owing to the confounding influence of expression from other cell types 20 . We therefore used a classification algorithm (randomforests) to identify optimal surrogate markers of co-stimulation/exhaustion modules in PBMC from autoimmune patients taken concurrently with the T cells described above ( Fig. 4a ). As the CD8 exhaustion and CD4 co-stimulation signatures were themselves correlated (Extended Data Fig. 3g -i), it became easier to detect their combined signal in PBMC using surrogate markers ( Fig. 4a and Extended Data Fig. 7 ). The top-ranked candidate, KAT2B, is a transcriptional co-activator known to mediate an antiapoptotic effect under conditions of metabolic stress and to increase cellular resistance to cytotoxic compounds. These characteristics, along with its high expression in memory and T-follicular helper and natural killer (NK) cells (Extended Data Fig. 8 ), suggest that it may mark the development of a durable, persistent T-cell phenotype promoting long-lived responses in either infection or autoimmunity. The observed association was confirmed both by technical replication (using the same samples run on an independent array platform) and by independent validation (Fig. 4b) .
To test whether similar associations may be apparent in multiple infectious and autoimmune diseases, we directly compared expression levels of KAT2B (and of the other top surrogate markers; Extended Data Fig. 9 ) between clinical subgroups defined within published studies for which PBMC expression and linked clinical outcome data were available. Where subgroups were not pre-specified, we compared clinical outcome in groups stratified as having either above-or belowmedian expression of KAT2B ( Fig. 4c-k) . Hierarchical clustering using all top surrogate markers gave similar stratification to that seen using KAT2B alone, while, as expected, the separation of subgroups of patients varied slightly in different clinical circumstances ( Fig. 4c -k and Extended Data Fig. 9 ).
Combined IFN and ribavirin therapy may result in increased virusspecific T-cell responses in chronic hepatitis C virus (HCV) infection, although such eradication therapy is successful in only 50% of cases 21 and in some no change in endogenous immune response is observed 22 . In a cohort of patients with hepatitis C receiving combination therapy, KAT2B expression was progressively induced and showed significantly greater induction in those ultimately responding to therapy ( Fig. 4c and Extended Data Fig. 10a ). In a clinical trial of malaria vaccination 23 , high KAT2B expression identified a subgroup with response rates of 78%, almost twice that of the low KAT2B expression group ( Fig. 4d and Extended Data Fig. 10b-d ). Moreover, response to vaccination for either influenza 24 ( Fig. 4e and Extended Data Fig. 10e -f) or yellow fever 25 (Fig. 4f ) could be predicted by stratifying recipients on the basis of their expression of KAT2B after exposure to vaccine. Dengue viral infection can result in a wide range of clinical manifestations ranging from asymptomatic infection or self-limiting fever (uncomplicated dengue) to dengue haemorrhagic fever (DHF). Consistent with our observations in autoimmunity, we observed that KAT2B expression was elevated in patients developing the excessive inflammatory response of DHF ( Fig. 4g) 26 .
We next asked whether surrogate detection of T-cell co-stimulation/ exhaustion modules could predict progression of other autoimmune diseases. Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by both autoantibodies and autoreactive CD4 T cells 27 . In a cohort of 75 patients with IPF 28 , high expression of KAT2B predicted subsequent progression to transplantation or death ( Fig. 4h ). We also observed that PBMC Kat2b expression was elevated in the murine NOD model of type 1 diabetes (T1D) 29 , with levels rising sharply during the T-cell initiation phase, long before the onset of diabetic hyperglycaemia (Extended Data Fig. 10g ). In a cohort of samples taken prospectively from children at high risk of disease but before its onset 30 , expression of KAT2B was seen to specifically and progressively rise ( Fig. 4i -k) both in patients who progressed to T1D and in those who developed islet-cell autoantibodies.
We show that the balance between co-stimulatory and co-inhibitory signals that shape T-cell exhaustion coincides with opposite clinical outcomes during autoreactive and anti-viral immunity. This at once allows prediction of outcome during infection and autoimmunity, and creates the potential for targeted therapeutic exhaustion of an autoimmune response in those predicted to follow an aggressive disease course. That this association is apparent in multiple autoimmune and inflammatory diseases emphasizes the importance of signals shaping T-cell exhaustion in driving risk of relapse or recurrence (prognosis) rather than disease susceptibility (diagnosis) or immediate severity (disease activity), and suggests that targeted manipulation of these processes may lead to new treatment strategies that extend beyond the conditions discussed here.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
No statistical methods were used to predetermine sample size. Ethical approval. Ethical approval for this study was obtained from the Cambridge Local Research Ethics Committee (reference numbers 04/023, 08/ H0306/21, 08/H0308/176) and informed consent was obtained from all subjects enrolled. Patients with AAV. Fifty-nine patients with AAV attending or referred to the specialist vasculitis unit at Addenbrooke's Hospital, Cambridge, UK, between July 2004 and May 2008 were enrolled into the present study. Active disease at presentation was defined by the BVAS 31 and the clinical impression that induction immunosuppression would be required. Prospective disease monitoring was undertaken monthly with serial BVAS disease scoring 31 and full biochemical, haematological and immunological profiling followed by treatment with an immunosuppressant and tapering dose steroid therapy (Supplementary Table 1 ). At each time-point of follow-up, disease activity was allocated into one of three categories defined as follows: (1) flare (at least one major or three minor BVAS criteria); (2) low-grade activity (no major and one or two minor BVAS criteria); (3) no activity (no major or minor BVAS criteria).
All disease flares were cross-checked against patient records to confirm clinical impression of disease activity and the need for intensified therapy as a result. Disease activity scoring was performed by a single investigator (E.F.M.) who was blinded to gene expression data at the time of scoring. Additional flares were defined in the absence of BVAS scoring if patients attended for emergency investigation (bronchoscopy, or specialist ophthalmological or ear/nose/throat surgical review) that confirmed evidence of active disease. To differentiate between discrete flares, clear improvement in disease activity was required in the form of an improvement in flare-related symptoms together with a reduction in BVAS score, a reduction in markers of inflammation (C-reactive protein, erythrocyte sedimentation rate) and a reduction in immunosuppressive therapy. Patients with SLE. The SLE cohort comprised 23 patients attending or referred to the Addenbrooke's Hospital specialist vasculitis unit between July 2004 and May 2008 who met at least four American College of Rheumatology SLE criteria 32 , presenting with active disease (defined below) and in whom immunosuppressive therapy was to be commenced or increased. After treatment with an immunosuppressant, patients were followed up monthly. Disease monitoring was undertaken with serial British Isles Lupus Assessment Group (BILAG) disease scoring 33 and full biochemical, haematological and immunological profiling (Supplementary Table 4 ).
A discrete disease flare required all three of the following prospectively defined criteria: (1) new BILAG score A or B in any system; (2) clinical impression of active disease by the reviewing physician; (3) the intention to increase immunosuppressive therapy as a result.
Additional flares were defined in the absence of BILAG scoring if patients were admitted directly to hospital as emergency cases for increased immunosuppressive therapy. To differentiate between disease flares, clear improvement in disease activity was required in the form of diminished flare-related symptoms together with a reduction in both BILAG score and immunosuppressive therapy. Patients with IBD. Patients with active Crohn's disease and ulcerative colitis were recruited from a specialist IBD clinic at Addenbrooke's Hospital, before starting treatment. Diagnosis was made using standard endoscopic, histological and radiological criteria 34 . Patients who had already received immunomodulators or corticosteroids were excluded. Enrolled patients were managed conventionally using a step-up strategy 3 .
Assessment of disease activity was in accordance with national and international guidelines and included consideration of symptoms, clinical signs and objective measures, including blood tests (C-reactive protein, erythrocyte sedimentation rate, haemoglobin concentration and serum albumin), stool markers (calprotectin) and mucosal assessment (by sigmoidoscopy or colonoscopy) where appropriate. Validated scoring tools were used as another means of assessing disease activity (Harvey-Bradshaw severity index 35 or simple clinical colitis activity index 36 for Crohn's disease and ulcerative colitis, respectively), although these were not used to guide treatment decisions. All clinicians were blinded to the microarray results.
For each disease, all patients were not included in all analyses as, for example, comparison of modular network analysis in related cell types required that samples passing quality control filtering were available for all cell types for all patients. Our previous publications have shown that the sample sizes used here are adequate to detect reproducible signatures correlating with clinical traits. Follow-up analysis. Comparisons of outcome and associated clinical variables between subgroups were analysed using a Kaplan-Meier log-rank test and a nonparametric Mann-Whitney U-test or a x 2 test as appropriate. Correction for multiple testing was applied using the Bonferroni method or FDR (Benjamini and Hochberg method) where appropriate as indicated. Cell separation and RNA extraction. Venepuncture was performed at a similar time of day in all cases to minimize gene expression differences arising from circadian variation 37 . PBMCs, CD4 and CD8 T cells were isolated from 110 ml of whole blood by centrifugation over ficoll and, for T cells, by positive selection using magnetic beads as previously described 20 . The purity of separated cell subsets was determined by flow cytometry and included as a covariate in downstream correlation and network analyses (for example, Fig. 1a , i). Total RNA was extracted from each cell population using an RNeasy mini kit (Qiagen) with quality assessed using an Agilent BioAnalyser 2100 and RNA quantification performed using a NanoDrop ND-1000 spectrophotometer. HsMediante 25k custom-spotted microarray. Total RNA (250 ng) was converted into double-stranded cDNA and labelled with Cy3-or Cy5-dCTP as previously described 20 . Appropriate Cy3-and Cy5-labelled samples were pooled and hybridized to custom-spotted oligonucleotide microarrays (HsMediante 25k) comprising probes representing 25,342 genes and control features 38 . All samples were hybridized in duplicate, using a dye-swap strategy, against a common reference RNA derived from pooled PBMC samples. After hybridization, arrays were washed and scanned on an Agilent G2565B scanner. Affymetrix Human Gene ST microarray. Aliquots of total RNA (200 ng) were labelled using Ambion WT Sense Target labelling kit and hybridized to Human Gene 1.0 or 1.1 ST Arrays (Affymetrix) as described. After washing, arrays were scanned using a GS 3000 or Gene Titan scanner (Affymetrix) as appropriate.
Published data sets. Published data sets were accessed through either National Center for Biotechnology Information (NCBI) Gene Expression Omnibus or ArrayExpress, imported into R using the Bioconductor package GEOquery and analysed as described. Search criteria incorporated the name of individual diseases and were filtered to human data sets but not by platform used. Studies were only included if they met the following criteria. (1) Similar quality control filters as applied to the data produced in-house were satisfied (described below).
(2) Samples were taken at an analogous time-point to those from which the co-stimulation and exhaustion signatures in autoimmunity were identified; that is, samples taken during active disease without concurrent immunosuppressive therapy. (3) Clinical outcome data were available.
It was not feasible to build a unified predictive model across all available data sets as they originated from different groups and were performed on mutually incompatible microarray platforms.
For the HCV data used in Fig. 4c , a marked response was defined as an HCV titre decrease greater than 3.5 log 10 (international units per millilitre (IU ml 21 )) and a poor response as an HCV titre decrease less than 1.5 log 10 (IU ml 21 ) by day 28 after commencing combined therapy with ribavirin and pegylated IFN-a. For the malaria vaccine trial used in Fig. 4d , 'protection' was defined as delayed or complete protection from subsequent confirmed Plasmodium falciparum infection after standardized exposure (five bites) compared with infectivity control subjects. For the influenza data used in Fig. 4e , protection was defined as at least one high response to at least one (of three) included strains. A high response was defined as at least a fourfold increase in haemagglutination inhibition titre at day 28 and a titre at least 1:40 as per US Food and Drug Administration guidelines.
All gene expression data used have been deposited in publicly available repositories (National Center for Biotechnology Information (NCBI) Gene Expression Omnibus and ArrayExpress): AAV, SLE (E-MTAB-2452, E-MTAB-157, E-MTAB-145), IBD (E-MTAB-331), LCMV (GSE9650), HCV (GSE7123), malaria vaccination (GSE18323), influenza vaccination (GSE29619), yellow fever vaccination (GSE13486), dengue fever (GSE25001), IPF (GSE28221), T1D (E-TABM-666), NOD (GSE21897), rheumatoid arthritis (GSE15258, GSE33377), in vitro CD8 stimulation (E-MTAB-3470). Data preprocessing and quality control. For HsMediante 25k arrays, raw image data were extracted using Koadarray version 2.4 software (Koada Technology) and probes with a confidence score .0.3 in at least one channel were flagged as present. Extracted data were imported into R where log transformation and background subtraction were performed followed by within-array print-tip Loess normalization and between-array quantile and scale normalization using the Limma package 39 in Bioconductor 40 . Further analysis was then performed in R and only data demonstrating a strong negative correlation (r 2 . 0.9) between dye swap replicates were used in downstream analyses.
Affymetrix raw data (.cel) files were imported into R and subjected to variance stabilization normalization using the VSN package in BioConductor 41 . Quality control was performed using the Bioconductor package arrayQualityMetrics 42 with outlying samples removed from downstream analyses. Correction for batch variation was performed using the Bioconductor package ComBat 43 and batch structure was included as a covariate in downstream correlation analyses.
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Clustering. Hierarchical clustering was performed using a Pearson correlation distance metric and average linkage analysis, performed either in Cluster with visualization in Treeview 44 , using Genepattern 45 , or directly in R using hclust in the statistics package. Differential expression. Differentially expressed genes were identified using linear modelling and an empirical Bayes method 39 using an FDR threshold of 0.05 as indicated to determine significance. Weighted gene co-expression network analysis. Highly correlated genes in immune cell subsets were identified and summarized with a modular eigengene profile using the weighted gene co-expression network analysis (WGCNA) bioconductor package in R 46 . Normalized, log-transformed expression data were variance-filtered using the inflexion point of a ranked list of median absolute deviation values for all probes. A soft thresholding power was chosen on the basis of the criterion of approximate scale-free topology 47 . Gene networks were constructed and modules identified from the resulting topological overlap matrix with a dissimilarity correlation threshold of 0.01 used to merge module boundaries and a specified minimum module size of n 5 30. Modules were summarized as a network of modular eigengenes, which were then correlated with a matrix of clinical variables and the resulting correlation matrix visualized as a heat map (Extended Data Fig. 1 ). As each module by definition comprises highly correlated genes, their combined expression may be usefully summarized by eigengene profiles 48 , effectively the first principal component of a given module (for example, Fig. 1b, f) . A small number of eigengene profiles may therefore effectively 'summarize' the principle patterns within the cellular transcriptome with minimal loss of information. This dimensionality-reduction approach also facilitates correlation of modular eigengenes with clinical traits (for example, Fig. 1a , i). Significance of correlation between a given clinical trait and a modular eigengene was assessed using linear regression with Bonferroni adjustment to correct for multiple testing (Extended Data Fig. 1 ). Independent association of a given module eigengene or gene expression profile (for example, KAT2B) with clinical outcome was assessed using a multiple linear regression model. Significance of each term in the linear model was plotted against its regression coefficient, as a measure of the strength of association (the regression coefficient reflecting the change in clinical outcome per unit change in modular/gene expression), for example Extended Data Fig. 3b -e.
Overlap of signatures with modules derived from network analysis is shown to the right of selected module heat maps ( Fig. 1a and Extended Data Fig. 2a , e, f) by the following formula to allow correction for variable module size: [(signature genes overlapping with module genes, n)/(genes in module, n)] 3 100. The overlap of randomly selected signatures of equivalent size was used as a control and is shown adjacent to the above plots. Hierarchical ordered partitioning and collapsing hybrid analysis. For validation purposes, highly correlated genes were independently partitioned into discrete modules using a second algorithm, hierarchical ordered partitioning and collapsing hybrid (HOPACH 49 ) in R. This approach differs from WGCNA in that it does not rely on a user-specified correlation threshold to define module boundaries but rather aims to maximize homogeneity of modules. Normalized, logtransformed data were clustered using a hierarchical algorithm with modular boundaries defined by the median split silhouette, a measure of how well-matched a gene is to the other genes within its current cluster versus how well-matched it would be if it were moved to another cluster. On partitioning the data set into clusters, each cluster is reiteratively subdivided until the median split silhouette is maximized, thereby producing an optimal segregation into maximally discrete modules. Knowledge-based network generation and pathway analysis. The biological relevance of gene groups composing modules identified by co-expression analysis was further investigated using the Ingenuity Pathway Analysis platform 50 . Six modules from the CD4 T-cell WGCNA analysis showed significant correlation with clinical outcome in AAV after correction for multiple testing (Bonferroni method; Supplementary Table 3 ). We applied network and pathway enrichment analysis to genes composing these modules to determine whether they may have any biological relevance. Briefly, for network analysis, genes from a specified target set of interest are progressively linked together on the basis of a measure of their interconnection, which is derived from described functional interactions. Additional highly interconnected genes that are absent from the target genes (open symbols) may be added to complete a network of arbitrary size (set at n 5 35). Networks may be ranked by significance which reflects the probability of randomly generating a network of similar size from genes included in the full knowledge database containing at least as many target genes as in the network in question. For pathways analysis, the over-representation of canonical pathways (pre-defined, well-characterized metabolic and signalling pathways curated from extensive literature reviews) among a specified set of target genes is assessed, with significance determined by computing a Fisher's exact test with FDR correction for multiple testing.
GSEA. GSEA 11 was used to further assess whether specific biological pathways or signatures were significantly enriched between subgroups of patients identified by gene modules (as opposed to testing for enrichment of pathways within modules themselves as outlined in the previous section). GSEA determines whether an a priori defined 'set' of genes (such as a signature) shows statistically significant cumulative changes in gene expression between phenotypic subgroups (such as patients with relapsing or quiescent disease). In brief, all genes are ranked on the basis of their differential expression between two groups then an enrichment score is calculated for a given gene set on the basis of how often its members appear at the top or bottom of the ranked differential list. One thousand random permutations of the phenotypic subgroups were used to establish a null distribution of enrichment score against which a normalized enrichment score and FDR-corrected q values were calculated. GSEA was run with a focused subgroup of gene signatures (as in Figs 2b and 3k) 11 selected to test the null hypothesis that different CD8 T-cell phenotypes were not significantly enriched in subgroups of patients identified by modular analysis. Selection of optimal PBMC-level biomarkers. Optimal surrogate markers facilitating identification of the CD4 T-cell co-stimulation/CD8 exhaustion signatures in PBMC-level data were determined using a random forests classification algorithm 51 (Fig. 4a ). Although signatures apparent in purified T-cell transcriptome data correlate with clinical outcome, they cannot be similarly detected in data derived from PBMC owing to the confounding influence of expression from other cell types; nor can the same genes be used to predict outcome in PBMC 2,20 . However, as CD4 T-cell co-stimulation and CD8 T-cell exhaustion signatures themselves showed close correlation, we hypothesized that this would amplify the signal detectable in PBMC and that detection of the combined CD4/CD8 T-cell response might be feasible. The availability of both separated T-cell and PBMC data from the same patients at the same time facilitates a supervised search for surrogate markers of the co-stimulation/exhaustion signatures in PBMC. Expression data derived both from CD4 T cells and from PBMC were available for a cohort of n 5 37 patients (AAV and SLE) after quality control and hybridization to the HsMediante 25k custom microarray platform and constituted a training cohort. Normalized, log-transformed expression data were analysed using the MLInterfaces Bioconductor package in R 52 . Using PBMC-level expression, data samples were classified into subgroups showing either high or low expression of the co-stimulation/exhaustion signature (as illustrated in Extended Data Fig. 5h , i) and probes were subsequently ranked using the variable importance metric on the basis of their ability to predict allocation to either group. The variable importance for a given gene reflects the change in accuracy of classification (percentage increase in MSE or increase in node purity) when that variable is randomly permuted. For a poorly predictive gene, random permutation of its values will minimally influence classification accuracy. Conversely, the most robust predictors will have a comparatively large effect on classification accuracy when randomly permuted. PBMC samples from a subset of n 5 37 cases derived from the training cohort were labelled and hybridized on an alternative microarray platform (Affymetrix Gene 1.0 ST) as a technical validation set ( Fig. 4b, left panel) . PBMC samples from an independent cohort of n 5 47 cases not included in the training cohort were labelled and hybridized to the Affymetrix Gene 1.0 ST platform as an independent test set ( Fig. 4b, right panel) . For both technical validation and independent test sets, expression of the optimal biomarker identified in Fig. 4a (KAT2B) was used to bisect the cohort relative to the median expression and clinical outcome was compared in patients with KAT2Bhi and KAT2Blo. Linear models. Linear modelling was performed in R using the statistics package. This took the form of fitv{lm(y*x1zx2zx3, data~mydata), where y (the response variable) was selected as normalized flare rate (flares per number of days follow-up, and x1-xn (the test variables) were selected to include measures of disease activity (both clinical scores and laboratory markers of inflammation), quantification of circulating leucocyte subsets (lymphocytes, neutrophils) and concurrent measurements of autoantibody titre where relevant. Test variables also included a biomarker profile (for example, exhaustion signature or KAT2B expression). The significance and magnitude (regression coefficient, reflecting change in response variable (flares per number of days follow-up) per unit change in each test variable included) were extracted and plotted against each other (for example, Extended Data Fig. 3b-e ). Not all clinical or laboratory measures were relevant comparisons in each case and therefore were not all included in every model generated. T-cell culture. Primary human CD8 T cells were separated from leucocyte cones obtained from NHS Blood and Transplant (Addenbrooke's Hospital) by centrifugation over ficoll and positive selection using magnetic beads as previously described 20 . The purity of separated cell subsets was determined by three-colour flow cytometry. Purified T cells were labelled with 10 mM CFSE (Invitrogen) and
RESEARCH LETTER
re-suspended in complete RPMI 1640 (Sigma Aldrich) in the presence of 10% FCS. Purified CD81 T cells (.95%) were then stimulated in sterile, 96-well U-bottomed culture plates (Greiner) using an 'artificial APC' consisting of MACS iBead particles (1:2 bead:cell ratio, Miltenyi) or DynaBead particles (Invitrogen) conjugated to either CD3/CD28 or CD2/CD3/CD28 as indicated in the presence of IL-2 (10 ng ml 21 , Gibco Life Technologies) for 6 days. The magnetic iBead construct was removed after 36 h in some instances as indicated.
In some experiments, additional co-stimulation was provided by the addition of either IFN-a (10 ng ml 21 , Abcam) or by additional conjugation of recombinant Human PD-L1 Fc Chimera (Life Technologies, 1 mg ml 21 ) or anti-CD40 antibody (50 ng ml 21 , Abcam) as indicated. The nature of co-stimulatory signals tested was based upon the results of the network analysis of CD4 T-cell modules described above ( Supplementary Table 2 ).
For re-stimulation experiments, cells were harvested on day 6 after stimulation and sorted into IL-7R hi and IL-7R lo populations (Extended Data Fig. 6d ) using a FACSAriaIII cell sorter (BD Biosciences) with live/dead discrimination performed using an AquaFluorescent amine-reactive dye (Invitrogen). Cell numbers were normalized and were re-suspended in complete RPMI 1640 (2 3 10 4 per millilitre, Sigma-Aldrich) and 'rested' in a sterile, U-bottomed culture plate (Greiner) for 6 days (37uC, 5% CO 2 ) before being re-stimulated (anti-CD2/3/28 1:2 bead:cell ratio, Miltenyi MACSiBead) for a further 6 days in the presence of IL-2 (10 ng ml 21 , Gibco Life Technologies).
Note that, as described in Extended Data Fig. 6g , human memory CD8 T-cell subsets do not equivalently respond to the stimulation conditions described above. As primary whole human CD8 T cells are composed of highly variable proportions of memory subsets and whole CD8 T cells were stimulated, it was necessary to perform paired tests of significance when comparing resulting T-cell subsets and transcriptional profiles. Flow cytometry. Immunophenotyping was performed using an LSR Fortessa analyser (BD Biosciences), and data were analysed using FlowJo software (Tree Star). Reactions were standardized with multicolour calibration particles (BD Biosciences) with saturating concentrations of the following antibodies: AquaFluorescent Live/Dead (Invitrogen), IL-7Ra AF647 (BD biosciences, clone HIL-7R-M21), PDCD1 APC (eBioscience, clone MIH4). For intracellular staining, cells were fixed and permeabilized using a transcription factor staining buffer set (eBioscience) and before staining with saturating concentrations of antibody against BCL2 (BD Biosciences, clone 100). a, Messenger RNA derived from purified leucocyte subsets sampled during active, untreated autoimmune disease is labelled and hybridized to a microarray platform (both HsMediante 25k and Affymetrix Gene 1.0 ST used here). Genes are then combined into modules (b, coloured blocks) based on the similarity of their expression profile in all samples. c, Detail for the 'black' module. Each horizontal black line represents expression of a single gene within the given module; y axis, gene expression; x axis, patient samples; red bar, eigengene profile which effectively summarizes the expression of all genes constituting the black module. d, Each modular profile is related to all others in a hierarchy that can itself be visualized by plotting correlation of all module eigengenes, such as in the heat map shown here. Coloured blocks represent individual modules, defined as in a. Modules are aligned in identical order on x and y axes with heat-map colour representing the correlation between each. Note that the diagonal (top left to bottom right) therefore represents the correlation of each eigengene profile with itself, and is always 1. Distance metric is the Euclidean distance. e, As each module is summarized by a representative eigengene profile, each may then be correlated against a range of clinical variables, allowing visualization of how the transcriptome relates to clinical variables, again in the form of a correlation heat map. Pearson correlation, r. f, Heat map showing gene expression modules (y axis) correlated against clinical variables (x axis) for the CD4 transcriptome in AAV. Pearson correlation, r. g, Heat map illustrating significance of correlations identified in f. P value threshold at Bonferronicorrected P , 0.05. Colour bar indicates actual P value of correlations deemed significant; grey shading, corrected P . 0.05. Significance for co-stimulation (black) module from Fig. 1 is also shown (P 5 0.0005). 
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Extended Data Figure 2 | Weighted gene co-expression network analysis of the T-cell transcriptome and its correlation with clinical phenotype in SLE. a, e, Heat maps illustrating the correlation of co-expression modules (coloured blocks, y axis) derived from the CD8 (a) and CD4 (e) transcriptomes of 23 SLE patients with clinical traits (x axis). Overlap of the previously described prognostic signature with co-expression modules, along with the distribution of a random signature of equivalent size, shown to the right of a (overlap 5 signature genes/module genes, as a percentage). Overlap of the CD4 T-cell co-stimulation 'black' module (defined in Fig. 1) shown to the right of e, with a randomly derived module and a type 1 IFN response signature previously shown to associate with active SLE 4 . Overlap shown as percentage representation of the signature within each module. b, d, Linear plots illustrating the 'charcoal' (b) and 'grey' (d) modules in detail; y axis, gene expression; x axis, individual patients; coloured lines (red, blue), module eigengenes. c, Correlation of SLE CD4 T-cell co-stimulation module eigengene (x axis, blue) against SLE CD8 T-cell prognostic signature (y axis, red). Pearson correlation, r, with P 5 two-tailed significance. f, Expanded detail from e, illustrating that modules corresponding to type 1 IFN response and costimulation signatures correlate with disease activity and outcome respectively but not vice versa. CD4 co-stimulation that correlate with clinical outcome, and how that relationship changes after treatment. a, A knowledge-based network analysis of 336 probes composing the 'black' expression module (Fig. 1e ) identifies a network of co-stimulation signalling ( Supplementary Table 3 Table 6 ) in AAV/SLE (d) and
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IBD (e). Clinical variables incorporated vary owing to differing relevance in each case but include some of the following: disease activity score (BVAS/ BILAG/CDAI/Harvey-Bradshaw score), C-reactive protein, autoantibody titre (PR3/MPO, dsDNA), lymphocyte count, neutrophil count, platelet count, IgG, IgA, IgM, erythrocyte sedimentation rate, age. f, Line plot showing mean expression of a CD8 T-cell exhaustion signature in 38 patients with AAV measured at presentation during active, untreated disease (t 0 ) and 12 months later when disease activity was quiescent and patients were on maintenance immunosuppressive therapy (t 12 ). Patients are grouped into those falling above (red) and below (blue) median expression of the exhaustion signature eigengene at entry. P 5 Mann-Whitney test comparing t 12 and t 0 values. The difference between the groups that is easily apparent at enrolment with active, untreated disease (t 0 ) is no longer apparent when disease is treated and quiescent 12 months later (t 12 ). g-i, Scatter plots showing inverse correlation between individual eigenvalues of the CD4 co-stimulation signature (x axis, red) and the CD8 exhaustion signature (y axis, blue) defined as in Fig. 2 , for AAV (g), SLE (h) and IBD (i) cohorts. Pearson correlation, r 2 , two-tailed significance. 8)). Detailed information on genes included in each signature is provided in Supplementary Table 6 . g, h, Wind rose plots showing relative enrichment (GSEA FDR q value) of distinct immune signatures between CD8 T cells from patients with melanoma, comparing CD8 from tumour-infiltrated lymph node with circulating CD8 T cells 16 . g, Enrichment of immune signatures from selected CD8 T-cell phenotypes; h, enrichment of signatures specifically up-/ downregulated by CD8 T-cell subsets derived from the LCMV model of T-cell exhaustion (acute LCMV Armstrong versus chronic LCMV Cl13 (ref. 8) ). Specific enrichment is seen for genes downregulated by exhausted cells but not for all genes upregulated by exhausted cells. c, Heat map showing differential expression of selected canonical co-inhibitory receptors (as for Fig. 2c (ref. 12) ) in the LCMV exhaustion model, between prognostic subgroups identified in Fig. 2d , g, j and between exhausted CD8 T cells from melanoma-infiltrated lymph node compared with circulating tumour-specific CD8 T cells 16 . Blue, up in exhausted; red, up in non-exhausted; grey, no significant change (FDR P , 0.05). 
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Extended Data Figure 7 | Top PBMC surrogate markers reflect expression of CD4 co-stimulation/CD8 exhaustion modules within CD4 and CD8 data respectively. Top PBMC-level predictors (n 5 13) were selected as indicated in Fig. 4a , and data are shown comparing expression of the optimal predictor (KAT2B, a, e) and of each other top predictor gene (d, h) in PBMC data compared with expression of the CD4 co-stimulation module eigengene in CD4 data (a-d) and the CD8 exhaustion signature eigengene in CD8 data (e-h) for n 5 44 patients with AAV. Significance of correlation: *P , 0.05, **P , 0.01, ***P , 0.001. b, f, Scatter plots showing the outcome of multiple linear regression models testing the association of KAT2B expression in CD4 (b) and CD8 (f) data (red symbols) directly compared with clinical markers of disease activity (black symbols); x axis, magnitude of association (regression coefficient, change in normalized flare rate (flares per number of days followup) per unit change in each variable tested); y axis, significance of association in multiple regression model; P, significance threshold (dashed red line, P 5 0.05). Clinical variables incorporated were disease activity score (BVAS), C-reactive protein, lymphocyte count, neutrophil count, IgG. c, g, Heat maps reproduced from Fig. 1a , i, respectively, showing overlap of top PBMC-level predictors with the modular analysis presented for CD4 (c) and CD8 (g) data in Fig. 1 . As expected, surrogate markers showed stronger correlation with the CD4 than the CD8 signature as the algorithm was trained to detect the CD4 co-stimulation module. 
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Extended Data Figure 9 | Hierarchical clustering of multiple data sets using 13 top PBMC-level surrogate markers of CD4 co-stimulation/CD8 exhaustion modules identifies subgroups of patients with distinct clinical outcomes. Replication of association between surrogate markers of CD4 co-stimulation/CD8 exhaustion signatures and clinical outcome (as shown in Fig. 4c -k) but using all top 13 PBMC-level surrogates rather than KAT2B alone. a, c, e, g, i, k, m, Heat maps showing hierarchical clustering of gene expression data of 13 top PBMC-level surrogate predictors of CD4 co-stimulation/CD8 exhaustion signatures (from Fig. 4a ) in patients with chronic HCV (a), during malaria vaccination (c), influenza vaccination (e), yellow fever vaccination (g), dengue fever infection (i), IPF (k) and pre-T1D (m). Subgroups were defined using a major division of the cluster dendrogram and group 1 allocated on the basis of KAT2B expression (highest in group 1). Clinical outcome associated with each subgroup identified is shown in b (HCV, percentage of responders to IFN-a/ribavirin therapy), d (percentage showing protection versus no protection from malaria vaccine), f (percentage response to influenza vaccination), h (yellow fever antibody-titre after vaccination), j (percentage progression to DHF), l (percentage of patients progressing to need for transplantation or death) and n (percentage of samples from patients with previous or subsequent progression to islet-cell antibody seroconversion or to a diagnosis of T1D). 
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